Cancers, Vol. 16, Pages 1481: EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer

In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein, suggesting that anti-EMP2 therapy may be beneficial for the treatment of select chemotherapy-resistant TNBC tumors.

Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Ann M. Chan Brian Aguirre Lucia Liu Vei Mah Justin M. Balko Jessica Tsui Navin P. Wadehra Neda A. Moatamed Mahdi Khoshchehreh Christen M. Dillard Meagan Kiyohara Yahya Elshimali Helena R. Chang Diana Marquez-Garban Nalo Hamilton Richard J. Pietras Lynn K. Tags: Article Source Type: research